Drug Profile
Daxibotulinumtoxin A - Revance Therapeutics
Alternative Names: DAXI; Daxibotulinumtoxin-A; DaxibotulinumtoxinA for Injection; DaxibotulinumtoxinA-lanm; DAXXIFY; RT-002Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Revance Therapeutics
- Developer Revance Therapeutics; Shanghai Fosun Pharmaceutical
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antispasmodics; Antispastics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Peptide drug conjugates; Skin disorder therapies; Urologics
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glabellar lines
- Registered Torticollis
- Phase II Muscle spasticity
- No development reported Skin disorders
- Discontinued Plantar fasciitis
Most Recent Events
- 08 Nov 2023 Revance Therapeutics plans to launch Daxibotulinumtoxin A for Torticollis (IM, Injection) in mid year 2024
- 08 Nov 2023 Revance Therapeutics expects approval of daxibotulinumtoxin A in China for the treatment of Glabellar lines in 2024
- 08 Nov 2023 Revance Therapeutics expects approval of daxibotulinumtoxin A in China for the treatment of Torticollis in 2024